Abstract 4142
Background
dNLR is a novel biomarker associated with clinical outcome in solid tumors including early stage breast cancer (BC). Here we report the association of dNLR with pCR in triple-negative (TN) and luminal BC patients (pts) treated with neoadjuvant CT.
Methods
This was a retrospective analysis of two randomized studies (GEICAM/2006-03 - NCT00432172 and ETNA - NCT01822314) involving 821 pts with early stage (>2cm) or locally advanced TN or luminal BC receiving anthracycline/taxane-based CT +/- carboplatin (GEICAM/2006-03) or nab-paclitaxel/paclitaxel followed by anthracycline regimen (ETNA). dNLR was calculated as the ratio of neutrophils and the difference between total leukocytes and neutrophils in peripheral blood before CT (baseline) and at the end of treatment (EOT). Logistic regression analyses were used to explore dNLR association with pCR at the two time points by molecular subtype.
Results
684 and 137 pts were from ETNA and GEICAM/2006-03 study respectively (TN n = 308; Luminal n = 513). In TN subgroup median baseline dNLR was 1.61 [interquartile range (IQR): 1.25-2.04] and at EOT 1.65 (IQR: 0.96-2.22). In luminal BC median baseline dNLR was 1.68 (IQR: 1.22-1.96) and at EOT 1.48 (IQR: 0.86-1.93). No association with pCR was found in luminal BC. Baseline dNLR was associated with pCR in TNBC in univariate analysis (OR: 0.709, CI: 0.5-1.006, p = 0.0406). At EOT significant association of dNLR as continuous variable with pCR was observed in TNBC both in univariate and multivariate analysis (OR: 0.665, CI: 0.501-0.884, p = 0.0034, n = 255 and OR: 0.62, CI: 0.406-0.946, p = 0.0231, n = 228 respectively). Quartiles distribution of EOT dNLR was also associated with pCR in univariate and multivariate analysis (Q1 vs combined Q2/Q3/Q4 group: OR: 0.32, CI: 0.17-0.64, p = 5e-04 and OR: 0.26, CI: 0.1-0.63, p = 0.002 respectively). Also a ROC curve - based optimal cut off method revealed significant association of EOT dNLR with pCR in TNBC (>2.231, OR: 0.43, CI: 0.25-0.74, p = 0.0035).
Conclusions
No association was found between dNLR and pCR in luminal BC. High dNLR levels at baseline and especially EOT seem to be associated with worse clinical outcome in TN tumors after neoadjuvant CT.
Clinical trial identification
GEICAM/2006-03 - NCT00432172: 07 Feb 2007 ETNA - NCT01822314: 02 Abr 2013.
Editorial acknowledgement
Legal entity responsible for the study
GEICAM Spanish Breast Cancer Group.
Funding
Has not received any funding.
Disclosure
M. Mansutti: Advisory / Consultancy: Celgene; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: AstraZeneca. A. Lluch: Research grant / Funding (self), Research grant / Funding (institution): Amgen; Research grant / Funding (self), Research grant / Funding (institution): AstraZeneca; Research grant / Funding (self), Research grant / Funding (institution): Boehringer-Ingelheim; Research grant / Funding (self), Research grant / Funding (institution): GSK; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Roche/Genentech; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Eisai; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Celgene; Research grant / Funding (self), Research grant / Funding (institution): Pierre-Fabre. M. Thill: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Genomic Health; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Amgen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Celgene; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Eisai; Honoraria (self): Hexal; Honoraria (self), Travel / Accommodation / Expenses: Medtronic; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Myriad; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: PFM Medical; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: RTI Surgical; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Teva; Advisory / Consultancy, Travel / Accommodation / Expenses: Biom-up; Advisory / Consultancy, Travel / Accommodation / Expenses: Lilly; Advisory / Consultancy, Travel / Accommodation / Expenses: Neodynamics; Advisory / Consultancy, Travel / Accommodation / Expenses: Norgine; Advisory / Consultancy, Travel / Accommodation / Expenses: Tesaro. L. Gianni: Advisory / Consultancy, MetIS, Novartis, Odonate Therapeutics, Revolution Medicine, Synaffix, Zymeworks: CONSULTANCY: ADC Therapeutics,; Advisory / Consultancy, RESEARCH FUNDING (institution): Zymeworks, Daiichi SankyoZymeworks, Daiichi Sankyo: AstraZeneca; Advisory / Consultancy, PATENTS, ROYALTIES: European Patent Application N. 12195182.6 and 12196177.5’, Roche: Celgene; Advisory / Consultancy: Lilly; Advisory / Consultancy: G1 Therapeutics; Advisory / Consultancy: Genentech; Advisory / Consultancy: Genomic Health; Advisory / Consultancy: MSD; Advisory / Consultancy: Oncolytics Biotech; Advisory / Consultancy: Odonate Therapeutics; Advisory / Consultancy: Onkaido; Advisory / Consultancy: Roche; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Tahio Pharmaceutical; Advisory / Consultancy: Sandoz; Advisory / Consultancy: SeaGen,; Advisory / Consultancy: Synthon; Advisory / Consultancy: Zymeworks,; Advisory / Consultancy: CD47; Advisory / Consultancy: GENENTA. All other authors have declared no conflicts of interest.
Resources from the same session
3006 - Nal-iri/lv5-fu versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study.
Presenter: Violaine Randrian
Session: Poster Display session 2
Resources:
Abstract
3697 - The expression of Versican and its role in pancreatic neuroendocrine tumor
Presenter: Zhao Sun
Session: Poster Display session 2
Resources:
Abstract
6073 - Characteristics of patients with thyroid carcinoma in the united states
Presenter: Dina El-Habashy
Session: Poster Display session 2
Resources:
Abstract
2124 - The discrimination of pituitary adenomas and craniopharyngioma on MRI: from image features to texture features
Presenter: Hanyue Xu
Session: Poster Display session 2
Resources:
Abstract
3786 - Proportion of Peripheral Lymphocyte Subsets Correlates with the Progression-free Survival and Metastatic Status of Pancreatic Neuroendocrine Tumor Patients
Presenter: Yitao Gong
Session: Poster Display session 2
Resources:
Abstract
2263 - Immunohistochemical expression of ER-α and PR in papillary thyroid carcinoma
Presenter: Enas Elkhouly
Session: Poster Display session 2
Resources:
Abstract
4386 - SILVELUL Project: Immunohistochemical panel analyses as potential predictive and prognostic factors in Pancreatic Neuroendocrine Tumors (PanNET) Treated with CAPTEM or Everolimus
Presenter: Ana De Jesus-Acosta
Session: Poster Display session 2
Resources:
Abstract
2302 - Carcinoid heart disease (CHD): the CRUSOE-NETs, a prospective cohort study from the French Group of Endocrine Tumors (GTE)
Presenter: Kathleen Dekeister Geoffroy
Session: Poster Display session 2
Resources:
Abstract
5749 - Safety of high doses of somatostatin analogs in well differentiated NENs in elderly
Presenter: Massimiliano Cani
Session: Poster Display session 2
Resources:
Abstract
3931 - Differences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumors (NETs).
Presenter: Jorge Hernando Cubero
Session: Poster Display session 2
Resources:
Abstract